MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ijnp/pyab088

Медицинская библиотека · The international journal of neuropsychopharmacology · 2022

Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).

Ekstrand Joakim, Fattah Christian, Persson Marcus, Cheng Tony, Nordanskog Pia, Åkeson Jonas, Tingström Anders, Lindström Mats B, Nordenskjöld Axel, Movahed Rad Pouya

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАEquivalence TrialПеревод пока не подготовлен

Аннотация

BACKGROUND

Ketamine has emerged as a fast-acting and powerful antidepressant, but no head to head trial has been performed, Here, ketamine is compared with electroconvulsive therapy (ECT), the most effective therapy for depression.

METHODS

Hospitalized patients with unipolar depression were randomized (1:1) to thrice-weekly racemic ketamine (0.5 mg/kg) infusions or ECT in a parallel, open-label, non-inferiority study. The primary outcome was remission (Montgomery Åsberg Depression Rating Scale score ≤10). Secondary outcomes included adverse events (AEs), time to remission, and relapse. Treatment sessions (maximum of 12) were administered until remission or maximal effect was achieved. Remitters were followed for 12 months after the final treatment session.

RESULTS

In total 186 inpatients were included and received treatment. Among patients receiving ECT, 63% remitted compared with 46% receiving ketamine infusions (P = .026; difference 95% CI 2%, 30%). Both ketamine and ECT required a median of 6 treatment sessions to induce remission. Distinct AEs were associated with each treatment. Serious and long-lasting AEs, including cases of persisting amnesia, were more common with ECT, while treatment-emergent AEs led to more dropouts in the ketamine group. Among remitters, 70% and 63%, with 57 and 61 median days in remission, relapsed within 12 months in the ketamine and ECT groups, respectively (P = .52).

CONCLUSION

Remission and cumulative symptom reduction following multiple racemic ketamine infusions in severely ill patients (age 18-85 years) in an authentic clinical setting suggest that ketamine, despite being inferior to ECT, can be a safe and valuable tool in treating unipolar depression.

Для цитирования: Ekstrand Joakim, Fattah Christian, Persson Marcus, Cheng Tony, Nordanskog Pia, Åkeson Jonas, Tingström Anders, Lindström Mats B, Nordenskjöld Axel, Movahed Rad Pouya. Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).. The international journal of neuropsychopharmacology. 2022. DOI: 10.1093/ijnp/pyab088.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.